Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

AML: KOL Insight: Update Bulletin [May 2017]

Product Code:
596200741
April Date:
May 2017
Format:
PDF
Price:
£1,140

This update bulletin  presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include: Novartis receiving US FDA approval for Rydapt (midostaurin) in newly diagnosed FLT3-mutated AML; the US FDA placing a clinical hold on several early stage studies of Seattle Genetics’ novel anti-CD33 antibody drug conjugate vadastuximab talirine (SGN-CD33A) in patients with AML; and Agios Pharmaceuticals and Celgene announcing that the US FDA has accepted their New Drug Application (NDA) for enasidenib (AG-221) for the treatment of patients with relapsed/refractory AML with an isocitrate dehydrogenase 2 (IDH2) mutation.

Business Questions:

  • How do KOLs view the FDA approval of the first FLT3 inhibitor Novartis’ Rydapt in AML? 
  • Could Rydapt capture market share in a wider population of patients; e.g. those without FLT3-mutated AML?
  • Do KOLs expect Rydapt to be utilised in the maintenance setting?
  • How do KOLs view the trade-off between efficacy and the risk of hepatotoxicity and death with Seattle Genetics’ vadastuximab, and should development of the drug continue?
  • How does vadastuximab compare to its discontinued predecessor Mylotarg?
  • How will combination trials inform the best positioning for vadastuximab and its developmental pathway?
  • What are the KOLs’ opinions on Agios/Celgene’s IDH2 inhibitor enasidenib in AML, and how likely is it that it will be approved this year by the US FDA?
  • If approved, do KOLs expect niche or widespread use of enasidenib in AML?
  • Will delays and logistical issues with companion diagnostic testing for targeted therapies be a barrier to use in the first-line setting of AML?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved